Enhancing tumor vaccines

Catalyzing MHC class II peptide exchange

Research output: Contribution to journalComment / DebateResearchpeer-review

Abstract

Evaluation of: Dickhaut K, Hoepner S, Eckhard J et al. Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer (MLE). PLoS One 4(9), e6811 (2009). Peptide vaccination strategies aimed at inducing CD4+ T-cell responses may be hampered due to the poorly receptive nature of MHC class II molecules to exogenous antigen. It has recently been reported that the small organic molecule adamantane ethanol, when included as an adjuvant in peptide vaccination, is capable of enhancing ligand exchange and markedly augmenting the subsequent antigen-specific CD4+ T-cell response. These results highlight a novel adjuvant strategy tested in vivo, which opens a further doorway to improving the efficacy of peptide vaccination and continuing the push towards clinical trials.

Original languageEnglish
Pages (from-to)129-132
Number of pages4
JournalExpert Review of Vaccines
Volume9
Issue number2
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

Keywords

  • Adamantane ethanol
  • HLA-DR
  • MHC-loading enhancer
  • Tumor-associated antigen

Cite this

@article{2603ee72e8bc43b18e61dd6e07365934,
title = "Enhancing tumor vaccines: Catalyzing MHC class II peptide exchange",
abstract = "Evaluation of: Dickhaut K, Hoepner S, Eckhard J et al. Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer (MLE). PLoS One 4(9), e6811 (2009). Peptide vaccination strategies aimed at inducing CD4+ T-cell responses may be hampered due to the poorly receptive nature of MHC class II molecules to exogenous antigen. It has recently been reported that the small organic molecule adamantane ethanol, when included as an adjuvant in peptide vaccination, is capable of enhancing ligand exchange and markedly augmenting the subsequent antigen-specific CD4+ T-cell response. These results highlight a novel adjuvant strategy tested in vivo, which opens a further doorway to improving the efficacy of peptide vaccination and continuing the push towards clinical trials.",
keywords = "Adamantane ethanol, HLA-DR, MHC-loading enhancer, Tumor-associated antigen",
author = "Croft, {Nathan P.} and Purcell, {Anthony W.}",
year = "2010",
month = "2",
doi = "10.1586/erv.09.159",
language = "English",
volume = "9",
pages = "129--132",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Taylor & Francis",
number = "2",

}

Enhancing tumor vaccines : Catalyzing MHC class II peptide exchange. / Croft, Nathan P.; Purcell, Anthony W.

In: Expert Review of Vaccines, Vol. 9, No. 2, 02.2010, p. 129-132.

Research output: Contribution to journalComment / DebateResearchpeer-review

TY - JOUR

T1 - Enhancing tumor vaccines

T2 - Catalyzing MHC class II peptide exchange

AU - Croft, Nathan P.

AU - Purcell, Anthony W.

PY - 2010/2

Y1 - 2010/2

N2 - Evaluation of: Dickhaut K, Hoepner S, Eckhard J et al. Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer (MLE). PLoS One 4(9), e6811 (2009). Peptide vaccination strategies aimed at inducing CD4+ T-cell responses may be hampered due to the poorly receptive nature of MHC class II molecules to exogenous antigen. It has recently been reported that the small organic molecule adamantane ethanol, when included as an adjuvant in peptide vaccination, is capable of enhancing ligand exchange and markedly augmenting the subsequent antigen-specific CD4+ T-cell response. These results highlight a novel adjuvant strategy tested in vivo, which opens a further doorway to improving the efficacy of peptide vaccination and continuing the push towards clinical trials.

AB - Evaluation of: Dickhaut K, Hoepner S, Eckhard J et al. Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer (MLE). PLoS One 4(9), e6811 (2009). Peptide vaccination strategies aimed at inducing CD4+ T-cell responses may be hampered due to the poorly receptive nature of MHC class II molecules to exogenous antigen. It has recently been reported that the small organic molecule adamantane ethanol, when included as an adjuvant in peptide vaccination, is capable of enhancing ligand exchange and markedly augmenting the subsequent antigen-specific CD4+ T-cell response. These results highlight a novel adjuvant strategy tested in vivo, which opens a further doorway to improving the efficacy of peptide vaccination and continuing the push towards clinical trials.

KW - Adamantane ethanol

KW - HLA-DR

KW - MHC-loading enhancer

KW - Tumor-associated antigen

UR - http://www.scopus.com/inward/record.url?scp=77950358770&partnerID=8YFLogxK

U2 - 10.1586/erv.09.159

DO - 10.1586/erv.09.159

M3 - Comment / Debate

VL - 9

SP - 129

EP - 132

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 2

ER -